Safety and Efficacy Profile of Tamoxifen for the Prevention of Breast Cancer: Systematic Review and Meta-analysis

View at publisher Summarise with VIRAT
Authors: Mutiur Rab, Aakriti Garg, Khushboo Bisht, Mohd Ashif Khan
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: The U.S. Food and Drug Administration (FDA) approved tamoxifen in 1977 for the prevention of breast cancer. Tamoxifen is effective against hormone receptor– positive breast cancer; however, its long-term safety in prevention settings continues to be evaluated. Methods: We systematically searched PubMed, ScienceDirect, and Embase from inception till April 2024 to identify eligible articles for the current study. Randomized Controlled Trials (RCTs) comparing tamoxifen with a comparator in healthy women or women at increased risk of breast cancer (≥18 years) were included in this Systematic Review and Meta-Analysis (SRMA). The Risk of Bias tool 2 (ROB2) was used to evaluate the quality of the included studies. Results: Out of 286 articles, 6 RCTs met the inclusion criteria. Tamoxifen significantly reduced the risk of invasive breast cancer (RR=0.74, 95% CI: 0.67-0.83, p

Fields of Study & Subjects

Estrogen and related hormone effects Cancer Risks and Factors Breast Cancer Treatment Studies

Publication details

Journal / source
Clinical Cancer Drugs
Volume
12
Publication date
21 March 2026
Language
EN